vs
InterDigital, Inc.（IDCC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
InterDigital, Inc.的季度营收约是再鼎医药的1.2倍（$158.2M vs $127.1M），再鼎医药同比增速更快（17.1% vs -37.4%），InterDigital, Inc.自由现金流更多（$528.6M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -22.5%）
InterDigital, Inc.是一家美国科技研发企业，成立于1972年，于纳斯达克挂牌上市，为标普600指数成分股，面向全球市场为移动设备、通信网络及相关服务领域提供无线与视频技术解决方案，在相关技术研发领域拥有深厚积累。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
IDCC vs ZLAB — 直观对比
营收规模更大
IDCC
是对方的1.2倍
$127.1M
营收增速更快
ZLAB
高出54.5%
-37.4%
自由现金流更多
IDCC
多$555.3M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-22.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $158.2M | $127.1M |
| 净利润 | $43.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 30.2% | -54.6% |
| 净利率 | 27.2% | — |
| 营收同比 | -37.4% | 17.1% |
| 净利润同比 | -67.7% | — |
| 每股收益（稀释后） | $1.07 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDCCZLAB
| Q4 25 | $158.2M | $127.1M | ||
| Q3 25 | $164.7M | $115.4M | ||
| Q2 25 | $300.6M | $109.1M | ||
| Q1 25 | $210.5M | $105.7M | ||
| Q4 24 | $252.8M | $108.5M | ||
| Q3 24 | $128.7M | $101.8M | ||
| Q2 24 | $223.5M | $100.1M | ||
| Q1 24 | $263.5M | $87.1M |
净利润IDCCZLAB
| Q4 25 | $43.0M | — | ||
| Q3 25 | $67.5M | $-36.0M | ||
| Q2 25 | $180.6M | $-40.7M | ||
| Q1 25 | $115.6M | $-48.4M | ||
| Q4 24 | $133.1M | — | ||
| Q3 24 | $34.2M | $-41.7M | ||
| Q2 24 | $109.7M | $-80.3M | ||
| Q1 24 | $81.7M | $-53.5M |
毛利率IDCCZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率IDCCZLAB
| Q4 25 | 30.2% | -54.6% | ||
| Q3 25 | 46.0% | -42.3% | ||
| Q2 25 | 68.3% | -50.3% | ||
| Q1 25 | 62.6% | -53.3% | ||
| Q4 24 | 64.3% | -62.6% | ||
| Q3 24 | 30.6% | -66.6% | ||
| Q2 24 | 59.9% | -76.0% | ||
| Q1 24 | 39.4% | -80.7% |
净利率IDCCZLAB
| Q4 25 | 27.2% | — | ||
| Q3 25 | 41.0% | -31.2% | ||
| Q2 25 | 60.1% | -37.3% | ||
| Q1 25 | 54.9% | -45.8% | ||
| Q4 24 | 52.7% | — | ||
| Q3 24 | 26.6% | -40.9% | ||
| Q2 24 | 49.1% | -80.2% | ||
| Q1 24 | 31.0% | -61.4% |
每股收益（稀释后）IDCCZLAB
| Q4 25 | $1.07 | $-0.05 | ||
| Q3 25 | $1.93 | $-0.03 | ||
| Q2 25 | $5.35 | $-0.04 | ||
| Q1 25 | $3.45 | $-0.04 | ||
| Q4 24 | $4.12 | $-0.09 | ||
| Q3 24 | $1.14 | $-0.04 | ||
| Q2 24 | $3.93 | $-0.08 | ||
| Q1 24 | $2.88 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $689.6M |
| 总债务越低越好 | $16.3M | — |
| 股东权益账面价值 | $1.1B | $715.5M |
| 总资产 | $2.1B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资IDCCZLAB
| Q4 25 | $1.2B | $689.6M | ||
| Q3 25 | $1.3B | $717.2M | ||
| Q2 25 | $937.0M | $732.2M | ||
| Q1 25 | $883.3M | $757.3M | ||
| Q4 24 | $958.2M | $779.7M | ||
| Q3 24 | $813.2M | $616.1M | ||
| Q2 24 | $760.3M | $630.0M | ||
| Q1 24 | $984.6M | $650.8M |
总债务IDCCZLAB
| Q4 25 | $16.3M | — | ||
| Q3 25 | $17.1M | — | ||
| Q2 25 | $16.6M | — | ||
| Q1 25 | $16.0M | — | ||
| Q4 24 | $15.4M | — | ||
| Q3 24 | $18.3M | — | ||
| Q2 24 | $17.7M | — | ||
| Q1 24 | $28.0M | — |
股东权益IDCCZLAB
| Q4 25 | $1.1B | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $936.9M | $810.8M | ||
| Q4 24 | $857.2M | $840.9M | ||
| Q3 24 | $722.5M | $667.7M | ||
| Q2 24 | $696.8M | $704.2M | ||
| Q1 24 | $624.3M | $762.2M |
总资产IDCCZLAB
| Q4 25 | $2.1B | $1.2B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.8B | $1.2B | ||
| Q3 24 | $1.7B | $985.3M | ||
| Q2 24 | $1.6B | $987.4M | ||
| Q1 24 | $1.8B | $988.4M |
负债/权益比IDCCZLAB
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.03× | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $544.5M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $528.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | 334.0% | -21.0% |
| 资本支出强度资本支出/营收 | 10.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 12.67× | — |
| 过去12个月自由现金流最近4个季度 | $994.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流IDCCZLAB
| Q4 25 | $544.5M | $-26.0M | ||
| Q3 25 | $395.9M | $-32.0M | ||
| Q2 25 | $105.1M | $-31.0M | ||
| Q1 25 | $-20.0M | $-61.7M | ||
| Q4 24 | $271.5M | $-55.8M | ||
| Q3 24 | $77.6M | $-26.8M | ||
| Q2 24 | $-48.9M | $-42.2M | ||
| Q1 24 | $50.8M | $-90.1M |
自由现金流IDCCZLAB
| Q4 25 | $528.6M | $-26.7M | ||
| Q3 25 | $395.3M | $-35.0M | ||
| Q2 25 | $104.5M | $-33.9M | ||
| Q1 25 | $-34.5M | $-63.2M | ||
| Q4 24 | $265.7M | $-58.4M | ||
| Q3 24 | $76.7M | $-28.2M | ||
| Q2 24 | $-49.5M | $-42.9M | ||
| Q1 24 | $50.3M | $-91.1M |
自由现金流率IDCCZLAB
| Q4 25 | 334.0% | -21.0% | ||
| Q3 25 | 240.1% | -30.4% | ||
| Q2 25 | 34.8% | -31.1% | ||
| Q1 25 | -16.4% | -59.9% | ||
| Q4 24 | 105.1% | -53.8% | ||
| Q3 24 | 59.6% | -27.7% | ||
| Q2 24 | -22.1% | -42.9% | ||
| Q1 24 | 19.1% | -104.5% |
资本支出强度IDCCZLAB
| Q4 25 | 10.0% | 0.5% | ||
| Q3 25 | 0.4% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 6.9% | 1.5% | ||
| Q4 24 | 2.3% | 2.4% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.3% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率IDCCZLAB
| Q4 25 | 12.67× | — | ||
| Q3 25 | 5.87× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | -0.17× | — | ||
| Q4 24 | 2.04× | — | ||
| Q3 24 | 2.27× | — | ||
| Q2 24 | -0.45× | — | ||
| Q1 24 | 0.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDCC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
